CDK

Cyclin-dependent kinases (CDKs) are the families of protein kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells.They are present in all known eukaryotes, and their regulatory function in the cell cycle has been evolutionarily conserved.

Cat. No.	Product name	CAS No.	Purity
T12642L	Simurosertib	1330782-76-7	99.82%
T12642L	Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).
T4417	LDC-4297 HCl (1453834-21-3(free base))	T4417	99.81%
T4417	LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.
T21588	Olomoucine	101622-51-9	99.8%
T21588	Olomoucine is an ATP competitive inhibitor of Cdk2/cyclin A, Cdc2/CyclinB, CDK2/CyclinE, CDK5/p35, and ERK1/p44 MAP kinase with IC50s of 7, 7, 7, 3 and 25 µM, re...
T2933	Wogonin	632-85-9	99.8%
T2933	Wogonin (Vogonin) is a cell-permeable and orally available flavonoid that displays anti-inflammatory and anticancer properties.
T10742	CDK9-IN-10	3542-63-0	99.8%
T10742	CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
T6239	Palbociclib monohydrochloride	827022-32-2	99.79%
T6239	Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 ad...
T72039	CLK1-IN-3	2922550-28-3	99.79%
T72039	Clk1-in-3 is a + selective and highly potent sexual Clk1 inhibitor with an IC50 of 5 nM and 300 pairs higher affinity than Dyrk1A. CLK1-IN-3 also showed highly e...
T23867	Cdc7-IN-7c	1330781-04-8	99.77%
T23867	Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.
T2463	ML141	71203-35-5	99.77%
T2463	ML141 (CID-2950007) is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM).
T1785	Palbociclib	571190-30-2	99.76%
T1785	Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has i...
T16363	NVP-2	1263373-43-8	99.76%
T16363	NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50...
T5358	Longdaysin	1353867-91-0	99.74%
T5358	Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 µM). It also can inhibit ERK2 (IC50: 52 µM).
T1912	Dinaciclib	779353-01-4	99.73%
T1912	Dinaciclib (SCH 727965) is a CDK inhibitor that selectively inhibits CDK1, CDK2, CDK5, and CDK9 (IC50 score = 3/1/1/4 nM). Dinaciclib has potential antitumor act...
T6081	Milciclib	802539-81-7	99.73%
T6081	Milciclib (PHA-848125) (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4...
T11878	LRRK2 inhibitor 1	1802525-61-6	99.73%
T11878	LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.
T3590	NSC23005	6314-70-1	99.71%
T3590	NSC23005 sodium is a p18INK inhibitor with potently promoted hematopoietic stem cell (HSC) expansion (ED50: 5.21 nM).
T3589	NSC23005 Sodium	1796596-46-7	99.71%
T3589	NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
T10736	CDK4/6-IN-2	1800506-48-2	99.7%
T10736	CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM).
T13202	Trilaciclib hydrochloride	1977495-97-8	99.69%
T13202	Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).
T4444	A-674563 HCl (552325-73-2(free base))	2070009-66-2	99.69%
T4444	A-674563 is an orally available, ATP-competitive, and reversible inhibitor of Akt (Ki: 11 nM for Akt1) [1]. It exhibits inhibitory activity against PKA and Cdk2 ...